Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Frédéric, Peyrade"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Michael Wang, Radhakrishnan Ramchandren, Robert Chen, Lionel Karlin, Geoffrey Chong, Wojciech Jurczak, Ka Lung Wu, Mark Bishton, Graham P. Collins, Paul Eliadis, Frédéric Peyrade, Yihua Lee, Karl Eckert, Jutta K. Neuenburg, Constantine S. Tam
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-8 (2021)
Abstract Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently a
Externí odkaz:
https://doaj.org/article/5a32b71647d74659993ff91287e58e85
Autor:
Thomas Chevalier, Amaury Daste, Esmaa Saada‐Bouzid, Anderson Loundou, Florent Peyraud, Tiphaine Lambert, Christophe Le Tourneau, Frédéric Peyrade, Charlotte Dupuis, Marc Alfonsi, Jérôme Fayette, Juliette Reure, Florence Huguet, Nicolas Fakhry, Clémence Toullec, Sébastien Salas
Publikováno v:
Cancer Medicine, Vol 10, Iss 12, Pp 3952-3963 (2021)
Abstract BACKGROUND Prognosis of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) remains poor. The addition of cetuximab, to platinum and fluorouracil chemotherapy (EXTREME regimen) has been shown to improve patients’ ou
Externí odkaz:
https://doaj.org/article/5723658a1a9f4460a7ff6b0ae310d7cc
Autor:
Joël Guigay, Emmanuel Chamorey, Gautier Lefebvre, Maciej Rotarski, Jean‐Philippe Wagner, Emmanuel Blot, Marc Alfonsi, Audrey Seronde, Jeltje Schulten, Frédéric Peyrade, Christophe Le Tourneau
Publikováno v:
Cancer Reports, Vol 5, Iss 2, Pp n/a-n/a (2022)
Abstract Background Cetuximab plus platinum‐based therapy (PBT) followed by cetuximab maintenance until progression (EXTREME) is a guideline‐recommended first‐line treatment option in recurrent/metastatic squamous cell carcinoma of the head and
Externí odkaz:
https://doaj.org/article/3a007a6916a0421394b2f19f01d92f4d
Autor:
Fabrice Jardin, Karen Leroy, Hervé Tilly, Gilles Salles, Nicolas Ketterer, Marc André, André Bosly, Frédéric Peyrade, Richard Delarue, Bertrand Coiffier, Bettina Fabiani, Danielle Canioni, Tony Petrella, Josette Brière, Christiane Copie-Bergman, Thierry Lamy, Corinne Haioun, Thierry Fest, Fabienne Desmots, Thierry J. Molina, Martin Figeac, Pauline Peyrouze, Jean-Philippe Jais, Catherine Maingonnat, Philippe Ruminy, Philippe Bertrand, Elodie Bohers, Sylvain Mareschal, Pierre-Julien Viailly, Sydney Dubois
Supplementary methods, figures, and tables Figure S1: Variant filters applied to Lymphopanel NGS data. Figure S2: Validation of variants according to SIFT and CADD scores. Figure S3: PMBL samples harbor more mutations than other DLBCL subtypes. Figur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9ed5037d866560467aa14d54f59aaa4
https://doi.org/10.1158/1078-0432.22458527
https://doi.org/10.1158/1078-0432.22458527
Autor:
Fabrice Jardin, Hervé Tilly, Thierry J. Molina, Gilles Salles, Karen Leroy, Nicolas Ketterer, Marc André, Frédéric Peyrade, Richard Delarue, Bettina Fabiani, Christiane Copie-Bergman, Thierry Lamy, Corinne Haioun, Thierry Fest, Fabienne Desmots, Martin Figeac, Pauline Peyrouze, Bruno Tesson, Jean-Philippe Jais, Dominique Penther, Jean-Michel Picquenot, Sylvain Mareschal, Catherine Maingonnat, Vinciane Marchand, Philippe Ruminy, Philippe Bertrand, Elodie Bohers, Pierre-Julien Viailly, Sydney Dubois
Supplementary Figures 1-10 Figure S1. MYD88 mutation VAF according to L265P or non-L265P variants. Figure S2. Age according to MYD88 mutation status and variant among ABC patients. Figure S3. Genomic profiles of DLBCL according to the presence of MYD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::827fe0b28212ad768b989f221e5a012e
https://doi.org/10.1158/1078-0432.22464410
https://doi.org/10.1158/1078-0432.22464410
Autor:
Fabrice Jardin, Hervé Tilly, Thierry J. Molina, Gilles Salles, Karen Leroy, Nicolas Ketterer, Marc André, Frédéric Peyrade, Richard Delarue, Bettina Fabiani, Christiane Copie-Bergman, Thierry Lamy, Corinne Haioun, Thierry Fest, Fabienne Desmots, Martin Figeac, Pauline Peyrouze, Bruno Tesson, Jean-Philippe Jais, Dominique Penther, Jean-Michel Picquenot, Sylvain Mareschal, Catherine Maingonnat, Vinciane Marchand, Philippe Ruminy, Philippe Bertrand, Elodie Bohers, Pierre-Julien Viailly, Sydney Dubois
Clinical characteristics of the 17 patients with CNS relapse are provided, included time to CNS relapse, first-line treatment and response after first-line treatment. CR, Complete Response; PR, Partial Response; PD, Progressive Disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fa4d7735bdc8aa889f2bbb51b5745b2
https://doi.org/10.1158/1078-0432.22464404
https://doi.org/10.1158/1078-0432.22464404
Autor:
Fabrice Jardin, Karen Leroy, Hervé Tilly, Gilles Salles, Nicolas Ketterer, Marc André, André Bosly, Frédéric Peyrade, Richard Delarue, Bertrand Coiffier, Bettina Fabiani, Danielle Canioni, Tony Petrella, Josette Brière, Christiane Copie-Bergman, Thierry Lamy, Corinne Haioun, Thierry Fest, Fabienne Desmots, Thierry J. Molina, Martin Figeac, Pauline Peyrouze, Jean-Philippe Jais, Catherine Maingonnat, Philippe Ruminy, Philippe Bertrand, Elodie Bohers, Sylvain Mareschal, Pierre-Julien Viailly, Sydney Dubois
Purpose: Next-generation sequencing (NGS) has detailed the genomic characterization of diffuse large B-cell lymphoma (DLBCL) by identifying recurrent somatic mutations. We set out to design a clinically feasible NGS panel focusing on genes whose muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1892cd8fb1dd9d95dbbcc3540a90e602
https://doi.org/10.1158/1078-0432.c.6523979.v1
https://doi.org/10.1158/1078-0432.c.6523979.v1
Autor:
Fabrice Jardin, Hervé Tilly, Thierry J. Molina, Gilles Salles, Karen Leroy, Nicolas Ketterer, Marc André, Frédéric Peyrade, Richard Delarue, Bettina Fabiani, Christiane Copie-Bergman, Thierry Lamy, Corinne Haioun, Thierry Fest, Fabienne Desmots, Martin Figeac, Pauline Peyrouze, Bruno Tesson, Jean-Philippe Jais, Dominique Penther, Jean-Michel Picquenot, Sylvain Mareschal, Catherine Maingonnat, Vinciane Marchand, Philippe Ruminy, Philippe Bertrand, Elodie Bohers, Pierre-Julien Viailly, Sydney Dubois
All relevant clinical data is included. Immunohistochemical results for BCL2, CD10, BCL6, MUM1, FOXP1, IgM and MYC are transcribed: 0 indicates negativity and 1 indicates positivity. For BCL2 and MYC, positivity is according to a threshold of 50% or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96470eaf5785d20760619314adc6fe6f
https://doi.org/10.1158/1078-0432.22464407
https://doi.org/10.1158/1078-0432.22464407
Autor:
Fabrice Jardin, Hervé Tilly, Thierry J. Molina, Gilles Salles, Karen Leroy, Nicolas Ketterer, Marc André, Frédéric Peyrade, Richard Delarue, Bettina Fabiani, Christiane Copie-Bergman, Thierry Lamy, Corinne Haioun, Thierry Fest, Fabienne Desmots, Martin Figeac, Pauline Peyrouze, Bruno Tesson, Jean-Philippe Jais, Dominique Penther, Jean-Michel Picquenot, Sylvain Mareschal, Catherine Maingonnat, Vinciane Marchand, Philippe Ruminy, Philippe Bertrand, Elodie Bohers, Pierre-Julien Viailly, Sydney Dubois
Purpose: MYD88 mutations, notably the recurrent gain-of-function L265P variant, are a distinguishing feature of activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL), leading to constitutive NFκB pathway activation. The aim of this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67c0e8bd84390b9f9a5264e15528cb06
https://doi.org/10.1158/1078-0432.c.6525698.v1
https://doi.org/10.1158/1078-0432.c.6525698.v1